⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 8, 2024Open Access

Figure S1 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors

Caroline E. Dravillas Samuel S. Coleman Rebecca Hoyd Griffin Caryotakis Louis Denko Carlos H.F. Chan Michelle L. Churchman Nicholas Denko Rebecca D. Dodd Islam Eljilany Sheetal Hardikar Marium Husain Alexandra P. Ikeguchi Ning Jin Qin Ma Martin D. McCarter Afaf E.G. Osman Lary A. Robinson Eric A. Singer Gabriel Tinoco Cornelia M. Ulrich Yousef Zakharia Daniel Spakowicz Ahmad A. Tarhini Aik Choon Tan

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

Association of CIBERSORT cell types with the response to ICIs

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Dravillas et al. (2024) studied this question.

synapsesocial.com/papers/68e5d11bb6db643587567580 https://doi.org/10.1158/2767-9764.26519617.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Table 1 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors2024
2Table 1 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors2024
3Figure S2 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors2024
4Figure S4 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors2024
5Figure 3 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors2024

More related papers

Figure 2 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors2024
Table S4 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors2024
Table S4 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors2024